Markus Hecker

Corporate Officer/Principal bei Ruprecht-Karls-Universität Heidelberg

Consumer Services

Health Technology

Aktive Positionen von Markus Hecker

Unternehmen	Position	Beginn	Ende
Ruprecht-Karls-Universität Heidelberg	Corporate Officer/Principal	05.11.2009	-
Ruprecht-Karls-Universität Heidelberg	Direktor/Vorstandsmitglied	-	05.11.2009

Unternehmen	Position	Beginn	Ende
Avontec GmbH Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.	Direktor/Vorstandsmitglied	01.08.2001	16.06.2010
	Gründer	05.11.2009	16.06.2010
University of Gottingen	Corporate Officer/Principal	01.01.1996	01.01.2004
University of Freiburg	Corporate Officer/Principal	-	-
St. Bartholomew's Hospital	Corporate Officer/Principal	-	-
Georgetown University	Corporate Officer/Principal	-	-

Universität Konstanz

Doctorate Degree

International

Operativ

Corporate Officer/Principal	5
Director/Board Member	2
Founder	1

Sektoral

Consumer Services	6
Health Technology	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Private Unternehmen	2
Avontec GmbH Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.	Health Technology
St. Bartholomew's Hospital

Private Unternehmen

Health Technology

St. Bartholomew's Hospital